This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Metz, J. M. Articles by Hahn, S. M. Search for Related Content PubMed PubMed Citation Articles by Metz, J. M. Articles by Hahn, S. M.

A Phase I Study of Topical Tempol for the Prevention of Alopecia Induced by Whole Brain Radiotherapy

Departments of ¹ Radiation Oncology and of ² Biostatistics and Epidemiology, University of Pennsylvania; and ³ Radiation Biology Branch, National Cancer Institute, NIH, Bethesda, MD

ABSTRACT

Purpose: Complete alopecia is a universal complication of whole brain radiation therapy which contributes to patient anxiety over treatment. Tempol, a nitroxide radioprotector, has been shown to protect against radiation-induced alopecia in an animal model. This phase Ib study was designed to evaluate the safety and side effect profile of topical Tempol in patients with brain metastases being treated with whole brain radiotherapy.

Experimental Design: Twelve patients with metastatic cancer to the brain were enrolled in the study between October 2000 and February 2003. Tempol (70 mg/ml concentration solution) was applied topically to the scalp 15 minutes before and washed off immediately after the completion of each of 10 fractions of whole brain radiation. Pharmacokinetic studies to evaluate the systemic absorption of Tempol were performed. Patients were assessed for toxicity before, during, and after Tempol administration. A secondary end point of the study, hair retention, was also scored.

Results: Eleven patients were treated with topical Tempol. Adverse events that were considered possibly, probably, or definitely related to Tempol, included asymptomatic grade 2 (two patients) and grade 1 (one patient) hypoglycemia, grade 1 forehead skin redness (one patient), grade 1 dry scalp (one patient), and grade 1 tingling sensation on the scalp (one patient). Tempol was not detected in blood samples from more than 50% of the patients. Mean maximum Tempol levels for individual patients at any time point varied from 0.4 to 3.1 µmol/L. Hair retention was localized to the base of the scalp where the Tempol solution pooled after application in the first four patients on the study. Subsequently, full scalp hair retention was seen in three of final five evaluable patients after gauze had been wrapped around the head to hold the solution against the scalp.

Conclusions: This study demonstrates that topical application of Tempol to the scalp before whole brain radiation is safe and well tolerated. Evidence of protection against radiation-induced alopecia was observed. A phase II study that uses a gel formulation to increase the exposure of scalp to Tempol has been initiated.

This article has been cited by other articles:

				D. S. Hoffmann, C. J. Weydert, E. Lazartigues, W. J. Kutschke, M. F. Kienzle, J. E. Leach, J. A. Sharma, R. V. Sharma, and R. L. Davisson Chronic Tempol Prevents Hypertension, Proteinuria, and Poor Feto-Placental Outcomes in BPH/5 Mouse Model of Preeclampsia Hypertension, April 1, 2008; 51(4): 1058 - 1065. [Abstract] [Full Text] [PDF]

				A. P. Cotrim, F. Hyodo, K.-I. Matsumoto, A. L. Sowers, J. A. Cook, B. J. Baum, M. C. Krishna, and J. B. Mitchell Differential Radiation Protection of Salivary Glands versus Tumor by Tempol with Accompanying Tissue Assessment of Tempol by Magnetic Resonance Imaging Clin. Cancer Res., August 15, 2007; 13(16): 4928 - 4933. [Abstract] [Full Text] [PDF]

				K.-i. Matsumoto, F. Hyodo, A. Matsumoto, A. P. Koretsky, A. L. Sowers, J. B. Mitchell, and M. C. Krishna High-Resolution Mapping of Tumor Redox Status by Magnetic Resonance Imaging Using Nitroxides as Redox-Sensitive Contrast Agents Clin. Cancer Res., April 15, 2006; 12(8): 2455 - 2462. [Abstract] [Full Text] [PDF]

				H. Utsumi, K.-i. Yamada, K. Ichikawa, K. Sakai, Y. Kinoshita, S. Matsumoto, and M. Nagai Simultaneous molecular imaging of redox reactions monitored by Overhauser-enhanced MRI with 14N- and 15N-labeled nitroxyl radicals PNAS, January 31, 2006; 103(5): 1463 - 1468. [Abstract] [Full Text] [PDF]

				A. P. Cotrim, A. L. Sowers, B. M. Lodde, J. M. Vitolo, A. Kingman, A. Russo, J. B. Mitchell, and B. J. Baum Kinetics of Tempol for Prevention of Xerostomia Following Head and Neck Irradiation in a Mouse Model Clin. Cancer Res., October 15, 2005; 11(20): 7564 - 7568. [Abstract] [Full Text] [PDF]

				K. Camphausen, D. Citrin, M. C. Krishna, and J. B. Mitchell Implications for Tumor Control During Protection of Normal Tissues With Antioxidants J. Clin. Oncol., August 20, 2005; 23(24): 5455 - 5457. [Full Text] [PDF]